We are international
Donate
• about myeloma TEXT SIZE   
   back

A Comprehensive Guide to Kos 2007
Review of the XIth International Myeloma Workshop
Summaries from the workshop sessions in Kos, Greece - 5–30 June, 2007
02.11.08
Click on the PDF icon in the upper right to read and/or download the document.


 related articles
KOS 2007: Molecular Principles Underlying Myeloma
KOS 2007: Molecular Lesions in Multiple Myeloma
KOS 2007: Towards a Molecular-Based Risk Stratification of Multiple Myeloma
KOS 2007: Clinical and Pathological Implications of Myeloma Subtypes
KOS 2007: Prognostic implications of FISH karyotyping in Myeloma
KOS 2007: Single Nucleotide Polymorphism Models in Myeloma - From the Bank On A Cure SNP Chip
KOS 2007: Animal Models of Multiple Myeloma: An Overview
KOS 2007: The Scid-hu model for Multiple Myeloma
KOS 2007: Chromosomal and epigenetic abnormalities in MGUS and MM Post-MGUS
KOS 2007: Microarray Analysis to Predict Response to Thalidomide and the IMIDs
KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches
KOS 2007: The Role of T-Cells in Multiple Myeloma
KOS 2007: Genetic Model of Multiple Myeloma
KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes
KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells
KOS 2007: Pathophysiology of Myeloma Bone Disease
KOS 2007: The Role of Bisphosphonates in the Management of Myeloma
KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration
KOS 2007: New Agents Targeting Myeloma Bone Disease
KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma
KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations
KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma
KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure
KOS 2007: International Staging System for Multiple Myeloma
KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy
KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy
KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy
KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant
KOS 2007: Management of Toxicities from Novel Agents
KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective?
Introduction
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? Yes!
KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? No!
KOS 2007: Establishment of an Amyloid-Forming Human Cell Line
KOS 2007: Targeting Beta 1 Integrin Mediated Survival Signals in Multiple Myeloma
KOS 2007: Response by SFLC and Marrow Flow Cytometry in MRC Myeloma IX
KOS 2007: Final Results of a Phase II PETHEMA Trial of Alternating Bortezomib and Dexamethasone as Induction Regimen Prior Autologous Stem Cell Transplantation (ASCT) in YOunger Patients with Multiple Myeloma (MM): Efficacy and Clinical Implications of Tumor Response Kinetics
KOS 2007: Long-Term and Updated Results of the IFM99-03 and IFM99-04 ProtocolsComparing Autologous Followed by RIC-Allogeneic Transplantation and Double Transplant in High-Risk De Novo Multiple Myeloma
KOS 2007: Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 patients from the Nordic Area
KOS 2007: Prognostic impact of postransplantation complete remission (CR) in multiple myeloma(MM). Final results of a prospective study in a series of homogenously treated patients
KOS 2007: Drug Resistance in Myeloma
KOS 2007: AKT as a Therapeutic Target in Multiple Myeloma
KOS 2007: DNA Vaccines to Suppress Myeloma
KOS 2007: Novel Immunotherapy Strategies in Multiple Myeloma
KOS 2007: Single VS Double Autologous Transplant
KOS 2007: Autologous Stem Cell Transplantation for MM: Analysis of Prognostic Factors
Kos 2007: Allogeneic Transplantation in Multiple Myeloma
KOS 2007: Donor lymphocyte infusion and other posttransplant Strategies After Allografting in Multiple Myeloma
KOS 2007: Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
KOS 2007: Solitary Bone and Extramedullary Plasmacytoma
KOS 2007: AL Amyloidosis: Diagnosis and Prognosis
KOS 2007: AL Amyloidosis: Response, Assessment, and Treatment
KOS 2007: The Role of High-Dose Therapy in AL-Amyloidosis
KOS 2007: Light Chain Deposition Disease
KOS 2007: What’s New About the POEMS Syndrome?
KOS 2007: Paraproteinemia Related Neuropathies
KOS 2007: High-Resolution Mapping of Common Gains and Losses in Myeloma
KOS 2007: Microchips for Optimized Fish Screening in Myeloma
KOS 2007: Gene Expression Profiles as Prognostic Factors for High-Dose Therapy and Bortezomib in Patients with Multiple Myeloma
KOS 2007: Cathepsin G is Upregulated in Patients Treated with IMIDS
KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Introduction
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? NO
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in mm? YES
KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Q & A
KOS 2007: The Importance of New and Evolving Response Criteria
KOS 2007: Individualizing Treatment in the Area of Multiple Novel Agents
KOS 2007: European Myeloma Network: The Present and the Future
KOS 2007: Future Perspectives in the Management of Myeloma


You might also be interested in:

KOS 2007: Molecular Principles Underlying Myeloma
P. Leif Bergsagel, MD
Mayo Clinic
Scottsdale, AZ, USA

KOS 2007: Molecular Lesions in Multiple Myeloma
Michael Kuehl, MD
National Cancer Institute
Bethesda, MD, USA

KOS 2007: Towards a Molecular-Based Risk Stratification of Multiple Myeloma
J.D. Shaughnessy Jr., MD
Donna D. and Donald M. Lambert Laboratory for Myeloma Genetics
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA

KOS 2007: Clinical and Pathological Implications of Myeloma Subtypes
Rafael Fonseca, MD
Mayo Clinic
Scottsdale, AZ, USA

KOS 2007: Prognostic implications of FISH karyotyping in Myeloma
Herve Avet-Loiseau, MD
Laboratory of Hematology
University Hospital
Nantes, France

KOS 2007: Single Nucleotide Polymorphism Models in Myeloma - From the Bank On A Cure SNP Chip
Brian Van Ness, PhD
Bank On A Cure®
International Myeloma Foundation

KOS 2007: Animal Models of Multiple Myeloma: An Overview
Karin Vanderkerken, MD
Vrije Universiteit Brussel (VUB)
Department Hematology and Immunology
Brussels, Belgium

KOS 2007: The Scid-hu model for Multiple Myeloma
Joshua Epstein, MD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, Arkansas, USA

KOS 2007: Chromosomal and epigenetic abnormalities in MGUS and MM Post-MGUS
Johannes Drach, MD
Medical University of Vienna
Department of Medicine I
Clinical Division of Oncology
Vienna, Austria

KOS 2007: Microarray Analysis to Predict Response to Thalidomide and the IMIDs
Shaji Kumar, MD
Mayo Clinic
Hepatology Department
Rochester, MN, USA

KOS 2007: Mosaicism of Vessels in Patients with Myeloma and Therapeutic Approaches
Angelo Vacca, MD
Department of Internal Medicine and Clinical Oncology
University of Bari Medical School
Bari, Italy

KOS 2007: The Role of T-Cells in Multiple Myeloma
Douglas Joshua, MD
University of Sydney
Royal Prince Alfred and Concord Hospital
Camperdown, Australia

KOS 2007: Genetic Model of Multiple Myeloma
Ruben Carrasco, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA
(Presentation given by Giovanni Tonon)

KOS 2007: From Oncogenome Mining to Functional Validation of Multiple Myeloma Cancer Genes
Giovanni Tonon, MD
Dana Farber Cancer Institute
Medical Oncology Dept.
Boston, MA, USA

KOS 2007: Induction of Multi-Lineage Markers and Their Down-Regulation by IL-6 in Human Myeloma Cells
Michio Kawano, MD
Laboratory of Cellular Signal Analysis
Graduate School of Medicine
Yamaguchi University
Ube, Japan

KOS 2007: Pathophysiology of Myeloma Bone Disease
Peter Croucher, MD
Section of Musculoskeletal Science
University of Sheffield Medical School
Sheffield, UK

KOS 2007: The Role of Bisphosphonates in the Management of Myeloma
James Berenson, MD
Institute for Myeloma and Bone Cancer Research
Los Angeles, CA, USA

KOS 2007: The Role of Biochemical Markers of Bone Metabolism in Multiple Myeloma. Adverse Events of Bisphosphonates Administration
Evangelos Terpos, MD
Department of Hematology & Medical Research
251 General Airforce Hospital
Athens, Greece

KOS 2007: New Agents Targeting Myeloma Bone Disease
G. David Roodman
University of Pittsburgh
Medicine/Hematology-Oncology
Pittsburgh, PA, USA

KOS 2007: A transgenic mouse model that faithfully reproduces the pathogenesis, biology and clinical features of multiple myeloma
Marta Chesi, MD
Comprehensive Cancer Center
Mayo Clinic Arizona
Scottsdale, AZ, USA

KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations
Paul Richardson, MD
Medical Oncology
Dana Farber Cancer Institute
Harvard Medical School
Boston, MA, USA

KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma
Donna Weber, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure
Heinz Ludwig, MD
Department of Medicine I
Center of Oncology and Hematology
Wilhelminenspital
Vienna, Austria

KOS 2007: International Staging System for Multiple Myeloma
Philip Greipp, MD
Mayo Clinic
Internal Medicine
Rochester, Minnesota

KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy
Michele Cavo, MD
Seràgnoli Institute of Hematology and Medical Oncology
Bologna UniversitySchool of Medicine
Italy

KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY, USA

KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy
Vincent Rajkumar, MD
Division of Hematology
Mayo Clinic
Rochester, Minnesota, USA

KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant
Thierry Facon, MD
CHU
Lille, France

KOS 2007: Management of Toxicities from Novel Agents
Mohamad Hussein, MD
Multiple Myeloma Clinical Research Clinical Director
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida, USA

KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies
Joan Bladé
Hematology Department
Institut of Hematology and Oncology
IDIBAPS, HospitalClínic
Barcelona, Spain

KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective?
Introduction
Raymond Alexanian, MD

KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? Yes!
Jean Luc Harousseau, MD
Hôpital Hôtel Dieu
Nantes, France

KOS 2007: Debate I - Should CR Achievement Be a Major Treatment Objective? No!
Mario Boccadoro, MD
Divisione di Ematologia dell’Università di Torino
Azienda Ospedaliera San Giovanni Battista
Torino, Italy

Includes questions and comments from the audience.

KOS 2007: Establishment of an Amyloid-Forming Human Cell Line
Bonnie Arendt, MD
Dept. of Immunology
Mayo Cinic
Rochester, MN, USA

KOS 2007: Targeting Beta 1 Integrin Mediated Survival Signals in Multiple Myeloma
Lori Hazlehurst, PhD
Moffitt Cancer Center
Tampa, Florida, USA

KOS 2007: Response by SFLC and Marrow Flow Cytometry in MRC Myeloma IX
Roger Owen, MD
HMDS Laboratory and Department of Haematology
Leeds Teaching Hospitals
Leeds, UK

KOS 2007: Final Results of a Phase II PETHEMA Trial of Alternating Bortezomib and Dexamethasone as Induction Regimen Prior Autologous Stem Cell Transplantation (ASCT) in YOunger Patients with Multiple Myeloma (MM): Efficacy and Clinical Implications of Tumor Response Kinetics
Laura Rosiñol, MD
Hospital Clinic
Barcelona, Spain

KOS 2007: Long-Term and Updated Results of the IFM99-03 and IFM99-04 ProtocolsComparing Autologous Followed by RIC-Allogeneic Transplantation and Double Transplant in High-Risk De Novo Multiple Myeloma
Philippe Moreau, MD
on Behalf of the IFM Group
France

KOS 2007: Double versus Single Autologous Stem-Cell Transplantation for Multiple Myeloma: a Region Based Study in 485 patients from the Nordic Area
H.E. Johnsen, MD
Department of Hematology
Huddinge University Hospital
Sweden

KOS 2007: Prognostic impact of postransplantation complete remission (CR) in multiple myeloma(MM). Final results of a prospective study in a series of homogenously treated patients
Joaquin Martinez-Lopez
the Grupo Espanol de Mieloma (GEM)
Spain

KOS 2007: Drug Resistance in Myeloma
W.S. Dalton, MD
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, USA

KOS 2007: AKT as a Therapeutic Target in Multiple Myeloma
Noopur Raje, MD
Massachusetts General Hospital Cancer Center
Boston, MA, USA

KOS 2007: DNA Vaccines to Suppress Myeloma
Freda Stevenson, MD
Molecular Immunology Group
Cancer Sciences Division
Tenovus Laboratory
Southampton University Hospitals Trust
Southampton, UK

KOS 2007: Novel Immunotherapy Strategies in Multiple Myeloma
Nikhil Munshi, MD
Dana Farber Cancer Institute
Boston MA, USA

KOS 2007: Single VS Double Autologous Transplant
Hartmut Goldschmidt, MD
Medizinischen Universitätsklinik und Poliklinik V
University of Heidelberg
Heidelberg, Germany

KOS 2007: Autologous Stem Cell Transplantation for MM: Analysis of Prognostic Factors
Hermann Einsele, MD
Medizinische Klinik und Poliklinik I
Bayerische Julius-Maximilians-Universität Würzburg

Kos 2007: Allogeneic Transplantation in Multiple Myeloma
Henk Lokhorst, MD
Dept. of Hematology
University Medical Center Utrecht, the Netherlands

KOS 2007: Donor lymphocyte infusion and other posttransplant Strategies After Allografting in Multiple Myeloma
Nikolaus Kröger
Dept. of Stem Cell Transplantation
University Hospital Hamburg-Eppendorf, Germany

KOS 2007: Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
Robert A. Kyle, MD
Mayo Clinic
Rochester, MN, USA

KOS 2007: Solitary Bone and Extramedullary Plasmacytoma
Raymond Alexanian, MD
M. D. Anderson Cancer Center
University of Texas
Houston, TX, USA


KOS 2007: AL Amyloidosis: Diagnosis and Prognosis
Giampaolo Merlini, MD
Amyloidosis Center
Fondazione IRCCS Policlinico San Matteo
University of Pavia
Pavia, Italy

KOS 2007: AL Amyloidosis: Response, Assessment, and Treatment
Morie A. Gertz, MD
Mayo Clinic
Rochester, MN, U.S.A.

KOS 2007: The Role of High-Dose Therapy in AL-Amyloidosis
Raymond Comenzo, MD
Hematology Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, NY, USA

KOS 2007: Light Chain Deposition Disease
Nelson Leung, MD
Mayo Clinic
Rochester, MN, USA

KOS 2007: What’s New About the POEMS Syndrome?
Angela Dispenzieri, MD
Mayo Clinic Cancer Center
Rochester, MN, USA

KOS 2007: Paraproteinemia Related Neuropathies
Eduardo Nobile-Orazio, MD
Department of Neurological Sciences
Milan University
Milan, Italy

KOS 2007: High-Resolution Mapping of Common Gains and Losses in Myeloma
Jonathan Keats,MD
Mayo Clinic Comprehensive Cancer Center
Scottsdale, Arizona, USA

KOS 2007: Microchips for Optimized Fish Screening in Myeloma
Vincent Sieben
Department of Electrical & Computer Engineering
University of Alberta
Edmonton, Canada

KOS 2007: Gene Expression Profiles as Prognostic Factors for High-Dose Therapy and Bortezomib in Patients with Multiple Myeloma
Annemiek Broyl, MD
Department of Hematology
Erasmus Medical Center
Rotterdam, The Netherlands

KOS 2007: Cathepsin G is Upregulated in Patients Treated with IMIDS
Suzanne Lentzsch, MD
University of Pittsburgh Cancer Institute
Pittsburgh, PA, USA

KOS 2007:Melphalan-Prednisone-Thalidomide (MP-T) is Also Superior to Melphalan-Prednisone (MP) in Patients 75 Years of Age or Older with Untreated Multiple Myeloma (MM). Preliminary Results of the Randomized, Double-Blind, Placebo Controlled IFM 01-01 Trial
Cyrille Hulin, MD
Itergroupe Francophone du Myélome

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Introduction
Jean Luc Harousseau, MD

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM? NO
Jean-Paul Fermand, MD
Department of Immuno-Hematology
Hopital Saint-Louis, France

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in mm? YES
Bart Barlogie, MD
Myeloma Institute for Research and Therapy
University of Arkansas for Medical Sciences
Little Rock, AR, USA

KOS 2007: Debate II - Should autologous transplant be part of the primary treatment in MM?
Q & A
Questions from Dr. Harousseau and the audience.

KOS 2007: The Importance of New and Evolving Response Criteria
Brian G.M. Durie, MD
Samuel Oschin Comprehensive Cancer Institute
Cedars Sinai Medical Center
Los Angeles, CA, USA

KOS 2007: Individualizing Treatment in the Area of Multiple Novel Agents
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain

KOS 2007: European Myeloma Network: The Present and the Future
Pieter Sonneveld
The European Myeloma Network (EMN)

KOS 2007: Future Perspectives in the Management of Myeloma
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute
Boston, MA, USA